Compositions and methods for inhibiting expression of Factor V Leiden mutant gene

Details for Australian Patent Application No. 2006311730 (hide)

Owner Alnylam Pharmaceuticals, Inc.

Inventors Vornlocher, Hans-Peter; Maraganore, John M.

Agent FB Rice

Pub. Number AU-B-2006311730

PCT Pub. Number WO2007/056331

Priority 60/735,759 09.11.05 US

Filing date 7 November 2006

Wipo publication date 18 May 2007

Acceptance publication date 2 December 2010

International Classifications

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

Event Publications

5 June 2008 PCT application entered the National Phase

  PCT publication WO2007/056331 Priority application(s): WO2007/056331

2 December 2010 Application Accepted

  Published as AU-B-2006311730

31 March 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006311734-Methods of sensitizing cancer to therapy-induced cytotoxicity

2006311729-Benzimidazole derivatives as gyrase inhibitors